Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO).
The Stelo glucose monitor for people with diabetes who are not taking insulin. [Image courtesy of Dexcom] After a busy 2024, Dexcom (Nasdaq:DXCM) Chair and CEO Kevin Sayer believes the company is set ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback